Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat
sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.